We are investigating the fairness of the proposed sale of Surgery Partners, Inc. (NASDAQ: SGRY) (“SGRY”) to HealthSpan Partners for $23.50 per share in cash.
The sale was approved upon the recommendation of a Special Committee of SGRY’s Board of Directors, which merits investigation into whether the members of the Special Committee were truly independent and disinterested.
Notably, while Surgery Partners’ public shareholders will be fully cashed out of their shares, SGRY’s largest stockholder, Bain Capital Investors (“Bain”), will roll over all of their SGRY shares in exchange for equity in the surviving entity, thus allowing Bain to remain invested in the business going forward. That opportunity is not being made available to SGRY’s public stockholders.
If you remain an SGRY stockholder and have concerns about the fairness of the proposed sale, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
“We are investigating whether the SGRY Board acted in the best interests of SGRY stockholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the members of the Special Committee that recommended the sale were independent and disinterested, whether the price is fair to SGRY stockholders and whether all material information regarding the transaction has been fully disclosed. We encourage SGRY stockholders to contact us if they have any concerns.”